ReviewAnnals of nuclear medicine2026
Non-metastatic castration-resistant prostate cancer in the epoch of PSMA-ligand PET/CT: twilight?
Review in Annals of nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of prostate-specific membrane antigen-ligand positron emission tomography/computerised tomography (PSMA-ligand PET/CT) into clinical practice has altered the prevalence of non‑metastatic (by conventional imaging) castration-resistant prostate cancer (nmCRPC). We herewith briefly review the biochemical and imaging parameters in nmCRPC and mainly focus on decoding disease localization using PSMA- ligand PET. The effective restaging with more accurate PSMA PET-based disease identification and characterization potentially signifies the entrance of the nmCRPC stage in the twilight zone. Moreover, it seems plausible that the small fraction of the nmCRPC invisible even on PSMA PET may constitute a latent phase of occult growth of the tumor cells. Supposedly, triggering of PSMA overexpression on the PCa cells under androgen deprivation therapy (ADT) through certain anticancer or other therapies such as protein kinase inhibitors (PKIs), dutasteride, or cholesterol-lowering regimes, might further hasten visualisation of micrometastases on PSMA-ligand PET, eventually transforming the nmCRPC stage into a defined, potentially curable target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.